Allos Therapeutics to release the entire registry for sufferers with PTCL Allos Therapeutics.

Allos Therapeutics to release the entire registry for sufferers with PTCL Allos Therapeutics, Inc eddrugs2018.com . today announced the launch of an international registry designed to address the urgent need to better understand treatment patterns and outcomes for patients with peripheral T-cell lymphoma . The registry, referred to as COMPLETE , is a worldwide observational study that will enroll individuals with newly-diagnosed PTCL and obtain data regarding longitudinal treatment patterns and outcomes. The registry will become launched during the 51st Annual Achieving of the American Culture of Hematology in New Orleans, LA. COMPLETE is designed to collect data on a real-time basis from individual healthcare practitioners over three years of individual enrollment and two years of follow up.